eCite Digital Repository

Optimized flow cytometric detection of transient receptor potential vanilloid-1 (TRPV1) in human hematological malignancies


Omari, SA and Geraghty, DP and Khalafallah, AA and Venkat, P and Shegog, Y and Ragg, SJ and de Bock, CE and Adams, MJ, Optimized flow cytometric detection of transient receptor potential vanilloid-1 (TRPV1) in human hematological malignancies, Medical Oncology, 39 Article 81. ISSN 1357-0560 (2022) [Refereed Article]

PDF (Published version)

Copyright Statement

The Author(s) 2022. his article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License, ( which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

DOI: doi:10.1007/s12032-022-01678-z


The ectopic overexpression of transient receptor potential vanilloid-1 (TRPV1) has been detected in numerous solid cancers, including breast, prostate, pancreatic, and tongue epithelium cancer. However, the expression of TRPV1 in hematological malignancies remains unknown. Here we show through in silico analysis that elevated TRPV1 mRNA expression occurs in a range of hematological malignancies and presents an optimized flow cytometry method to rapidly assess TRPV1 protein expression for both cell lines and primary patient samples. Three anti-TRPV1 antibodies were evaluated for intracellular TRPV1 detection using flow cytometry resulting in an optimized protocol for the evaluation of TRPV1 in hematological malignant cell lines and patients' peripheral blood mononuclear cells (PBMC). Overexpression of TRPV1 was observed in THP-1 (acute monocytic leukemia) and U266B1 (multiple myeloma, MM), but not U937 (histiocytic lymphoma) compared to healthy PBMC. TRPV1 was also detected in all 49 patients including B-cell non-Hodgkin's lymphoma (B-NHL), MM, and others and 20 healthy controls. TRPV1 expression was increased in 8% of patients (MM = 2, B-NHL = 2). In conclusion, we provide an optimized flow cytometry method for routine expression analysis of clinical samples and show that TRPV1 is increased in a subset of patients with hematological malignancies.

Item Details

Item Type:Refereed Article
Keywords:flow cytometry, hematological malignancies, leukemia, RNA-seq, transient receptor potential vanilloid-1 (TRPV1), western blotting
Research Division:Biomedical and Clinical Sciences
Research Group:Oncology and carcinogenesis
Research Field:Cancer cell biology
Objective Division:Health
Objective Group:Clinical health
Objective Field:Prevention of human diseases and conditions
UTAS Author:Omari, SA (Dr Sofia Omari)
UTAS Author:Geraghty, DP (Professor Dominic Geraghty)
UTAS Author:Khalafallah, AA (Professor Alhossain Khalafallah)
UTAS Author:Shegog, Y (Ms Yvette Shegog)
UTAS Author:Ragg, SJ (Dr Scott Ragg)
UTAS Author:Adams, MJ (Dr Murray Adams)
ID Code:149976
Year Published:2022
Web of Science® Times Cited:1
Deposited By:Health Sciences
Deposited On:2022-05-04
Last Modified:2022-09-19
Downloads:4 View Download Statistics

Repository Staff Only: item control page